Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease characterised by fibrosis and scarring of lung tissue. Current approved therapeutics having limited efficacy and severe adverse effects. This thesis investigates the activation of the prostacyclin receptor (IPR), as a potential therapeutic approach for the treatment of IPF. Using targeted FRET biosensors to investigate cAMP and ERK signalling with high spatial and temporal resolution, a complex relationship was discovered between IPR signalling and phenotypic outcome The most significant result was the reversal of efficacy at phenotypically relevant readouts, demonstrating that sustained cAMP signalling may be important for IPF therapeutics.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.